{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:22Z","timestamp":1761895882174},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T00:00:00Z","timestamp":1405036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s11033-014-3559-x","type":"journal-article","created":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T21:07:14Z","timestamp":1405026434000},"page":"6737-6742","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis"],"prefix":"10.1007","volume":"41","author":[{"given":"G\u00fcven","family":"Cetin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuba","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seda","family":"Turgut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ali Cikrikcioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cem Ar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mesut","family":"Ayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayhan","family":"Unlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevda Rabia","family":"Celik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahya","family":"Sekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cumali","family":"Karatoprak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,11]]},"reference":[{"key":"3559_CR1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/asheducation-2011.1.215","volume":"2011","author":"F Cervantes","year":"2011","unstructured":"Cervantes F (2011) Management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2011:215\u2013221. doi: 10.1182\/asheducation-2011.1.215","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3559_CR2","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.1007\/s11033-012-1721-x","volume":"39","author":"M Karkucak","year":"2012","unstructured":"Karkucak M, Yakut T, Ozkocaman V, Ozkalemkas F, Ali R, Bayram M, Gorukmez O, Ocakoglu G (2012) Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera. Mol Biol Rep 39:8663\u20138667","journal-title":"Mol Biol Rep"},{"issue":"9","key":"3559_CR3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"RL Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7(9):673","journal-title":"Nat Rev Cancer"},{"key":"3559_CR4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5505\/tjh.2012.03780","volume":"29","author":"\u00d6 Mehtap","year":"2012","unstructured":"Mehtap \u00d6, Ate\u015fo\u011flu EB, Tarkun P, G\u00f6n\u00fcll\u00fc E, Keski H, Top\u00e7u Y, \u00dcz\u00fclmez N, S\u00fcnnet\u00e7i D, Hac\u0131hanefio\u011flu A (2012) The association between gene polymorphisms and leukocytosis with thrombotic complications in patients with essential thrombocythemia and polycythemia vera. Turk J Hematol 29:162\u2013169","journal-title":"Turk J Hematol"},{"key":"3559_CR5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.10634","volume":"92","author":"G Finazzi","year":"2007","unstructured":"Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T, Ematologia UO, Riuniti O (2007) Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 92:135\u2013136","journal-title":"Haematologica"},{"key":"3559_CR6","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","volume":"19","author":"E Antonioli","year":"2005","unstructured":"Antonioli E, Guglielmelli P, Pancrazzi A et al (2005) Clinical implications of the JAK2V617F mutation in essential thrombocythemia. Leukemia 19:1847\u20131849","journal-title":"Leukemia"},{"issue":"17","key":"3559_CR7","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1002\/cncr.24440","volume":"115","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Thiele J, Vardiman JW (2009) The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 115(17):3842","journal-title":"Cancer"},{"key":"3559_CR8","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS et al (2005) Gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u201317790","journal-title":"N Engl J Med"},{"key":"3559_CR9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"3559_CR10","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434:1144\u20131148","journal-title":"Nature"},{"key":"3559_CR11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387\u2013397","journal-title":"Cancer Cell"},{"key":"3559_CR12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11845-007-0026-x","volume":"176","author":"SE Langabeer","year":"2007","unstructured":"Langabeer SE, Ni Ainle F, Conneally E, Lawler M (2007) Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. Ir J Med Sci 176:105\u2013109","journal-title":"Ir J Med Sci"},{"key":"3559_CR13","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945\u20131953","journal-title":"Lancet"},{"key":"3559_CR14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1179\/102453309X12473408860226","volume":"14","author":"AL Basquiera","year":"2009","unstructured":"Basquiera AL, Soria NW, Ryser R et al (2009) Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology 14:323\u2013330","journal-title":"Hematology"},{"issue":"2","key":"3559_CR15","doi-asserted-by":"crossref","first-page":"e57856","DOI":"10.1371\/journal.pone.0057856","volume":"8","author":"J Zhou","year":"2013","unstructured":"Zhou J, Ye Y, Zeng S, Zhou Y, Mao Z, Song X, Ying B, Lu X, Jiang H, Wang L (2013) Impact of JAK2V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts. PLoS ONE 8(2):e57856","journal-title":"PLoS ONE"},{"key":"3559_CR16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/147323000903700105","volume":"37","author":"YM Shen","year":"2009","unstructured":"Shen YM, Chao HY, Zhang R et al (2009) Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders. J Int Med Res 37:37\u201346","journal-title":"J Int Med Res"},{"key":"3559_CR17","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","volume":"280","author":"R Zhao","year":"2005","unstructured":"Zhao R, Xing S, Li Z, Li Q (2005) Krantz SB, Zhao ZJ Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788\u201322792","journal-title":"J Biol Chem"},{"key":"3559_CR18","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.patbio.2009.06.005","volume":"59","author":"A Benmoussa","year":"2011","unstructured":"Benmoussa A, Dehbi H, Fehri S, Quessar A, Nadifi S (2011) JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects. Pathol Biol 59:e89\u2013e92","journal-title":"Pathol Biol"},{"key":"3559_CR19","first-page":"2109","volume":"87","author":"SJ Zhang","year":"2007","unstructured":"Zhang SJ, Li WD, Song JH, Xu W, Qiu HX, Li JY (2007) The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis. Zhonghua Yi Xue Za Zhi 87:2109\u20132112","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"2","key":"3559_CR20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1445-5994.2010.02199.x","volume":"41","author":"GC Wong","year":"2011","unstructured":"Wong GC, Kam GL, Koay ES (2011) JAK2 mutations in Asian patients with essential thrombocythaemia. Intern Med J 41(2):191\u2013196","journal-title":"Intern Med J"},{"key":"3559_CR21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","volume":"106","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Lasho TL, Schwager SM et al (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera. Cancer 106:631\u2013636","journal-title":"Cancer"},{"key":"3559_CR22","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","volume":"106","author":"J Jelinek","year":"2005","unstructured":"Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prehal JT, Verstovsek S (2005) JAK2 mutation 1849G\u2192T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome negative CML, and megakaryocytic leukemia. Blood 106:3370\u20133373","journal-title":"Blood"},{"key":"3559_CR23","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood-2006-03-008805","volume":"108","author":"AR Moliterno","year":"2006","unstructured":"Moliterno AR, Donna MW, Ophelia R, Spivak JL (2006) Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 108:3913\u20133915","journal-title":"Blood"},{"key":"3559_CR24","first-page":"21","volume":"8","author":"A Patriarca","year":"2010","unstructured":"Patriarca A, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A (2010) Is the absence of JAK2V617F mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients. Blood Transfus 8:21\u201327","journal-title":"Blood Transfus"},{"key":"3559_CR25","first-page":"347","volume":"43","author":"B Poopak","year":"2013","unstructured":"Poopak B, Farshdousti Hagh M, Saki N, Elahi F, Rezvani H, Khosravipour G, Jahangirpour Ma, Bolouri S, Golkar T, Falah P (2013) JAK2 V617F mutation in Iranian patients with myeloproliferative neoplasms: clinical and laboratory findings. Turk. J Med Sci 43:347\u2013353","journal-title":"J Med Sci"},{"key":"3559_CR26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3343\/alm.2012.32.6.385","volume":"32","author":"JS Ha","year":"2012","unstructured":"Ha JS, Kim YK, Jung SI, Jung HR, Chung IS (2012) Correlations between janus kinas 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ann Lab Med 32:385\u2013391","journal-title":"Ann Lab Med"},{"issue":"9","key":"3559_CR27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.medcli.2012.03.032","volume":"139","author":"AE Kerguel\u00e9n Fuentes","year":"2012","unstructured":"Kerguel\u00e9n Fuentes AE, Hern\u00e1ndez-Maraver D, Lombardia L, Canales Albendea MA, Rodriguez de la R\u00faa A (2012) Clinical significance of the quantification of JAK2 V617F allele burden in classical Ph-negative myeloproliferative neoplasms. Med Clin (Barc) 139(9):373\u2013378","journal-title":"Med Clin (Barc)"},{"issue":"5","key":"3559_CR28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/09537104.2011.630112","volume":"23","author":"E Arellano-Rodrigo","year":"2012","unstructured":"Arellano-Rodrigo E, Alvarez-Larr\u00e1n A, Reverter JC, Villamor N, Jou JM et al (2012) Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. Platelets 23(5):336\u2013343","journal-title":"Platelets"},{"issue":"9","key":"3559_CR29","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2011-02-339655","volume":"118","author":"M Panova-Noeva","year":"2011","unstructured":"Panova-Noeva M, Marchetti M, Buoro S, Russo L, Leuzzi A et al (2011) JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood 118(9):2599\u20132601","journal-title":"Blood"},{"key":"3559_CR30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5603\/FHC.2011.0037","volume":"49","author":"B Soko\u0142owska","year":"2011","unstructured":"Soko\u0142owska B, Nowaczy\u0144ska A, Bykowska K, Chocholska S, Wejksza K et al (2011) JAK2 mutation status, hemostatic risk factors and thrombophilic factors inessential thrombocythemia (ET) patients. Folia Histochem Cytobiol 49:267\u2013271","journal-title":"Folia Histochem Cytobiol"},{"issue":"3","key":"3559_CR31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","volume":"128","author":"MA Elliott","year":"2005","unstructured":"Elliott MA, Tefferi A (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128(3):275","journal-title":"Br J Haematol"},{"issue":"11","key":"3559_CR32","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1182\/blood-2005-08-3526","volume":"107","author":"AI Schafer","year":"2006","unstructured":"Schafer AI (2006) Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 107(11):4214","journal-title":"Blood"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-014-3559-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-014-3559-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-014-3559-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T03:15:44Z","timestamp":1559358944000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-014-3559-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,11]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["3559"],"URL":"https:\/\/doi.org\/10.1007\/s11033-014-3559-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,11]]}}}